Xilio Therapeutics (XLO) Interest Expenses (2020 - 2026)
Xilio Therapeutics (XLO) posted Interest Expenses of $19000.0 for Q1 2026, down 29.63% sequentially from $27000.0 in Q4 2025, and down 67.8% YoY from $59000.0 in Q1 2025.
Xilio Therapeutics (XLO) Interest Expenses (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Interest Expenses for 7 years, with the latest figure at $19000.0 in Q1 2026.
- Quarterly Interest Expenses fell 67.8% year-over-year to $19000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19000.0 (down 67.8% YoY) and the FY2025 annual result came in at $125.4 million, up 11.48% from the prior year.
- Interest Expenses declined to $19000.0 in Q1 2026 per XLO's latest filing, from $27000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $1.3 million in Q4 2022 and troughed at $19000.0 in Q1 2026.
- A 5-year average of $210764.7 and a median of $175000.0 in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 1154.0% in 2022, down 98.61% in 2022.
- Over 5 years, Interest Expenses stood at $1.3 million in 2022, then sank by 81.98% to $226000.0 in 2023, then advanced by 24.78% to $282000.0 in 2024, then plunged by 90.43% to $27000.0 in 2025, then retreated by 29.63% to $19000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $19000.0, $27000.0, and $68000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129,000.00 |
| Jun 30, 2026 | 129,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Sep 30, 2024 | 99,000.00 |
| Sep 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Mar 31, 2024 | 314,000.00 |
| Mar 31, 2024 | 314,000.00 |